Form 4: Neumora Therapeutics Officer Jason Duncan Reports Stock Option Grant and Repricing

Jason Duncan, Chief Legal and Administrative Officer of Neumora Therapeutics, reports the grant of new stock options and the repricing of existing options.

Summary

• Jason Duncan, Chief Legal and Administrative Officer of Neumora Therapeutics, filed a Form 4 detailing changes in beneficial ownership.
• On February 13, 2025, Duncan was granted stock options for 500,000 shares at an exercise price of $1.69, vesting over four years from the Vesting Commencement Date.
• On February 13, 2025, the Board approved the repricing of Duncan's existing stock options for 400,000 shares from an exercise price of $12.97 to $1.69, contingent on stockholder approval.
• The repricing is subject to Duncan remaining in service to the Issuer through August 13, 2026.
• The options vest 25% on the first anniversary of the Vesting Commencement Date and then 1/48th monthly thereafter.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The stock option grant is a positive incentive, but the repricing suggests potential past underperformance. The contingency on stockholder approval adds uncertainty.

Positives

• The grant of new stock options and repricing of existing options may incentivize the officer to remain with the company.
• The vesting schedule aligns the officer's interests with the long-term performance of the company.

Negatives

• The repricing of options could be viewed negatively by some shareholders if it is perceived as rewarding poor performance.
• The repricing is contingent on stockholder approval, which may not be guaranteed.

Risks

• The repricing is subject to stockholder approval, and if not approved, the original terms of the options will remain in place.
• The officer's continued service through August 13, 2026, is required for the repricing to remain in effect; departure before this date would void the repricing.

Future Outlook

The repricing is contingent on stockholder approval and the officer's continued service through August 13, 2026.

Industry Context

Stock option grants and repricings are common practices to incentivize and retain key personnel in the biotechnology industry, particularly in companies focused on long-term drug development.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in publicly traded companies, particularly in the biotech sector.
• Repricing of options is less common but can occur when a company's stock price has significantly declined, as it helps to restore the incentive value of the options.
• Similar companies like Biogen, Amgen, and Gilead Sciences also utilize stock options as part of their executive compensation packages.

Stakeholder Impact

• Shareholders may be impacted by the potential dilution from the stock options and the repricing decision.
• Employees may be impacted by the potential for similar repricing actions for their own stock options.
• The officer is incentivized to improve company performance to increase the value of the stock options.

Next Steps

• Stockholder vote on the option repricing.
• Continued vesting of the stock options according to the specified schedule.

Key Dates